Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Swedish Boost For Life Sciences Innovation Resonates Around Europe

This article was originally published in The Pink Sheet Daily

Executive Summary

Sweden’s government has allocated 4 billion kroner for the R&D sector and SEK 600 million specifically for life science in the hopes of rejuvenating Swedish R&D and getting the nation back on the top rankings of medicine innovation. It’s a theme being heard in other European countries.

You may also be interested in...



National Strategy For Biomedical Innovation Simmering On Hamburg’s Agenda

FDA commissioner says all stakeholders need to come to the table to develop a path for maintaining U.S. preeminence in making medical discoveries and moving them through the pharmaceutical pipeline into patients’ hands.

Sweden’s Reference Pricing Proposal: A Five-Year Doomsday Clock For Innovation?

Sweden may link its existing value-based pricing system with international reference pricing to cut drug expenditure, a move the pharmaceuticals industry says would devastate domestic R&D there.

German Joy For Pharma As Drug Discount Prices Stay Hidden

The updated German Pharmaceutical Act will ensure that drug prices negotiated there between pharmaceutical manufacturers and health insurers will remain hidden from public view, as Germany’s government seeks to avoid a pan-European drug price crash.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS074638

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel